NCT06760702 - A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients with Colorectal, Ovarian, and Renal Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 9, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

May 31, 2027

Conditions

Ovarian CancerColorectal CancerRenal Cancer

Interventions

DRUG

AUR109 200mg

AUR109 200mg (once daily)

DRUG

AUR109 300mg

AUR109 300mg once daily

DRUG

AUR109 400mg

AUR109 400mg once daily

Trial Locations (5)

RECRUITING

Uro-Science Centre, S.P. Medical College & AG of Hospitals, Bikaner

RECRUITING

Kiran Multi Super Speciality Hospital and Research Centre, Surat

RECRUITING

Sunshine Global Hospitals, Surat

RECRUITING

Sujan Surgical Cancer Hospital and Amravati Cancer Foundation, Amravati

RECRUITING

Gindodi Devi Hospital, Khursīpār